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AbsTrACT
Objective To gain an understanding of the variation 
in available resources and clinical practices between 
neonatal units (NNUs) in the low-income and middle-
income country (LMIC) setting to inform the design 
of an observational study on the burden of unit-level 
antimicrobial resistance (AMR).
Design A web-based survey using a REDCap database 
was circulated to NNUs participating in the Neonatal 
AMR research network. The survey included questions 
about NNU funding structure, size, admission rates, 
access to supportive therapies, empirical antimicrobial 
guidelines and period prevalence of neonatal blood 
culture isolates and their resistance patterns.
setting 39 NNUs from 12 countries.
Patients Any neonate admitted to one of the 
participating NNUs.
Interventions This was an observational cohort study.
results The number of live births per unit ranged from 
513 to 27 700 over the 12-month study period, with the 
number of neonatal cots ranging from 12 to 110. The 
proportion of preterm admissions <32 weeks ranged 
from 0% to 19%, and the majority of units (26/39, 66%) 
use Essential Medicines List ’Access’ antimicrobials as 
their first-line treatment in neonatal sepsis. Cephalosporin 
resistance rates in Gram-negative isolates ranged from 
26% to 84%, and carbapenem resistance rates ranged 
from 0% to 81%. Glycopeptide resistance rates among 
Gram-positive isolates ranged from 0% to 45%.
Conclusion AMR is already a significant issue in NNUs 
worldwide. The apparent burden of AMR in a given 
NNU in the LMIC setting can be influenced by a range 
of factors which will vary substantially between NNUs. 
These variations must be considered when designing 
interventions to improve neonatal mortality globally.
InTrODuCTIOn
Between 2000 and 2015 there was a significant 
decline in global neonatal mortality, from 36 to 19 
per 1000 live births (5.1–2.7 million cases annu-
ally).1 This was less pronounced than the reduction 
seen in childhood (<5 years) mortality, highlighting 
What is already known on this topic?
 ► The majority of neonatal pathogens in the UK 
setting are susceptible to antimicrobials used as 
empirical treatment for neonatal sepsis.
 ► The Delhi Neonatal Infection Study 
demonstrated high levels of resistance of 
neonatal pathogens to antimicrobials used as 
empirical treatment for neonatal sepsis in Delhi.
 ► The prevalence of extended-spectrum beta-
lactamase (ESBL) Gram-negative infections in 
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Figure 1 Factors affecting the apparent burden of antimicrobial resistance (AMR) in the neonatal setting.
What this study adds?
 ► For the first time, this study describes multinational, 
multicentre variation in empirical antimicrobial choice for 
neonatal sepsis, with a focus on low-income and middle-
income settings.
 ► This study is the first to describe multinational, multicentre 
rates of antimicrobial resistance in both Gram-negative and 
Gram-positive isolates from neonatal units.
 ► This study is the first to show high rates of cephalosporin and 
carbapenem resistance in isolates, particularly those from 
Bangladesh and South Africa.
room for improvement. Antimicrobial resistance (AMR) 
threatens progress towards this goal.
Laxminarayan et al2 previously estimated the global AMR 
population-attributable fraction for neonatal mortality. It was 
assumed that low-income and middle-income countries (LMICs) 
consistently use a combination of a narrow-spectrum penicillin 
(benzylpenicillin/ampicillin) and aminoglycoside (gentamicin/
amikacin) as empirical therapy for neonatal sepsis (in line with 
the WHO guidelines), and local resistance rates to either anti-
microbial drug could be used as a proxy for risk of mortality 
attributable to AMR. Mortality rates for AMR neonatal infec-
tions were taken from the published literature. Their analysis 
suggested that 214 000 of 690 000 annual neonatal deaths 
(31%) associated with sepsis are potentially attributable to AMR. 
Morbidity and mortality due to AMR have since been added to 
the Global Burden of Disease Study.3
These estimates are likely to represent an overestimate of 
mortality attributable to AMR, as blood cultures are usually 
taken in an inpatient setting where infants are more unwell; it 
is difficult to accurately estimate mortality from AMR sepsis 
in the community setting. The limited availability of global 
microbiological data means that national estimates of resistance 
may be extrapolated from one or two studies only. Resistance 
patterns are also known to vary widely between units within 
cities, particularly when prescribing practices differ substan-
tially.4 These factors illustrate the need for detailed multicountry, 
patient-level data to better characterise the relationship between 
AMR and mortality.
A number of factors may affect the burden of resistant infec-
tions in the neonatal setting (figure 1). They can be divided into 
three broad categories: resource availability, clinical presentation 
and clinical decision-making.
The Neonatal AMR research network (NeoAMR) project was 
established in September 2017. It aims to ‘develop new, glob-
ally applicable, empiric antibiotic regimens and strategies for the 
treatment of neonatal sepsis in settings with varying prevalence 
of multidrug-resistant pathogens’.5 These include establishing a 
global network of neonatal units (NNUs) to design and conduct 
studies on the optimal use of off-patent antibiotics and other 
clinical interventions to reduce AMR infection. NNUs should be 
a mix of neonatal intensive care and special care beds, depending 
on local demand and resource availability. To facilitate this, a 
web-based survey was designed to gain an understanding of how 
the above three factors varied between different settings.
MeThODs
The NeoAMR web-based survey collected data from 39 NNUs 
across 12 countries in four continents, with contact made 
through existing networks. Participating centres were provided 
with either a PDF (portable document format) copy of the 
survey or an online link to the REDCap6 database, with ques-
tions focused on issues concerning unit capacity, staffing ratios, 
availability of services, use of antimicrobial guidelines, choice of 
empirical antimicrobial regimens, local laboratory facilities and 
antimicrobial susceptibility rates. NNUs also provided informa-
tion about the total number of positive blood cultures, species 
isolated and antimicrobial sensitivity testing performed over 12 
months. We did not collect data on the rate of culture collection.
The WHO Essential Medicines List (EML) 2017 was revised 
to include three new categories for antimicrobials—‘Access’, 
‘Watch’ and ‘Reserve’, to denote the order (first-line, second-
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Table 1 Summary statistics for NeoAMR centres (per year)
Country units (n)
Total number of live 
births/year (inborn)

















Bangladesh 3 5764 (945–4819) 5883 (945–2828) 33 60 0.5–0.8 35 13
Brazil 3 4620 (820–3800) 986 (290–434) 20 20 0.1–1.5 43 17
Cambodia 1 0* 437 12 36 1.7 16 0
China 6 38 228 (11 000–14 328) 14 248 (1632–3700) 103 30 0.4–1.3 29 14
Colombia 1 2478 1127 41 27 0.95 72 17
Greece 2 1657 (529–1128) 731 (202–529) 26 15 0.1–0.8 40 14
India 9 80 400 (513–27 717) 513–5503 49 50 0.5–2.0 40 14
Nigeria 1 1462 808 32 25 0.6 40 17
South Africa 4 40 838 (7850–19 219) 10 244 (1195–4806) 110 23 0.6–1.2 72 19
Thailand 6 29 005 (1718–9434) 11 852 (165–4620) 66 40 0.5–2.6 21 3
Uganda 1 23 174 6182 52 119 0.4 46 0
Vietnam 1 0* 4200 90 47 1.1 29 10
There was only one site for Cambodia, Columbia, Nigeria, Uganda and Vietnam.
*0 denotes circumstances where the neonatal unit was not affiliated with an onsite labour ward and there were no live births on site.
NeoAMR, Neonatal AMR research network; WTE, whole-time equivalent.
ensure that the appropriate antibiotics are prescribed for a 
given infection.7 We analysed our results according to these 
categories.
The survey covered a timeframe of 12 months, where rele-
vant, and data were collected between June and September 
2017. All data were anonymised and hosted on a server at St 
George’s, University of London. All participating sites agreed to 
the remote hosting of clinical data.
resulTs
resource availability
Of the 39 units, 38 were university or teaching hospitals. Twen-
ty-five were publicly funded, or free at the point of access, eight 
were funded by a mixture of public/private incomes, and six 
were private, that is, a fee for service was payable by the patient. 
The 39 units serve a total of 228 580 live births per year, of 
whom 84 140 babies were admitted (both inborn and outborn) 
and 37 500 (45%) were born preterm (<37 weeks). Summary 
statistics for the 39 centres are shown in table 1.
Of the 39 units, 35 provided intubation and ventilation 
routinely (1 provided intubation and ventilation on a non-rou-
tine basis, 3 could provide non-invasive ventilation, of which 1 
provided non-invasive ventilation on a non-routine basis). Thir-
ty-six centres were capable of providing inotropic support, and 
34 had the facilities to provide total parenteral nutrition. Thir-
ty-three centres had routine support from a paediatric surgical 
team, three centres had non-routine support from a surgical 
team, and three centres had no access to a paediatric surgical 
team. Seven units were not associated with a maternity unit on 
site; the average percentage of preterm admissions <37 weeks 
was 26%. On this basis, the majority of units would be cate-
gorised as level 3 units, as defined by the American Academy 
of Pediatrics or the British Association of Perinatal Medicine 
(BAPM).8 On average, each unit had 38 admissions per cot per 
annum (IQR 22–50); however, the unit in Uganda was an outlier 
with 119 admissions per cot.
Access to laboratory facilities was good across the network, 
with blood culturing taking place at all sites apart from Uganda. 
Antimicrobial susceptibility testing was taking place at 31 of 39 
sites.
Clinical presentation
The ratio of nurses to cots, as well as the proportion of preterm 
admissions, determines the workload and influences the ability 
of medical staff to recognise unwell infants. Table 1 demon-
strates that there does not appear to be an association between 
units with higher nurse to cot ratios and those with higher 
proportions of preterm admissions. Although we do not have 
data on the intensity of bed usage (ie, whether they are used in a 
high-dependency or special care capacity), our data suggest that 
on average there is approximately one whole-time equivalent 
nurse employed per cot for the participating units. On average, 
participating units had on average 0.78 (IQR 0.52–1.25) full-
time nurses per cot, and as our data included both intensive care 
and low dependency beds this would suggest that the 1:1 ratio 
for intensive care beds recommended by the BAPM8 is being met.
Clinical decision-making
Local or national guidelines for empirical antibiotic use in early-
onset sepsis (EOS) or late-onset sepsis (LOS) were available in 
the majority of centres (29 of 38). Fewer guidelines were avail-
able for neonatal meningitis (22 of 38). Of 38 centres, 24 used 
the WHO-recommended combination of a broad-spectrum 
penicillin with aminoglycoside (benzylpenicillin/ampicillin with 
gentamicin/amikacin) as first-line therapy in EOS. Table 2 shows 
the empirical antibiotic regimens grouped according to the three 
EML categories. Choice of antimicrobials tended to cluster by 
geographical region; there was less compliance with WHO guid-
ance overall in Bangladesh, China and India. There was no clear 
association between the level of preterm admissions and choice 
of antimicrobial regimen. Seventeen NeoAMR centres listed 
WHO ‘Reserve’ antibiotics as a choice on their empirical anti-
microbial guidelines (for either EOS, LOS or meningitis). This 
suggests that use of ‘Reserve’ antibiotics is already established 
in NNUs as empirical therapy. A full list of empirical antibiotic 
regimens for NeoAMR centres can be found in online supple-
mentary appendix 1.
The majority of centres reserved the use of broader spectrum 
antibiotics for LOS and meningitis. However, there was signif-
icant variation in the use of ‘Watch’ antibiotics in particular. 
Overall, 43% of empirical antimicrobial regimens consist of 
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Table 2 Empirical antimicrobial regimens, categorised by EML-C 
group
Country
 eOs  lOs  Meningitis
A W r A W r A W r
Bangladesh 3/3 3/3 3/3
Brazil 3/3 3/3 1/3 2/3
Cambodia 1/1 1/1 1/1
China 5/6 1/6 3/6 3/6 4/6 2/6
Colombia 1/1 100 100
Greece 2/2 2/2 1/2 1/2
India 6/9 3/9 5/9 3/9 1/9 3/9 6/9
Nigeria 1/1 1/1 1/1
South Africa 4/4 2/4 2/4 3/4 1/4
Thailand 6/6 1/6 4/6 1/6 1/6 4/6 1/6
Uganda 1/1 1/1 1/1
Vietnam 1/1 1/1 1/1
A, Access; EML-C, Essential Medicines List for Children; EOS, early-onset sepsis; LOS, late-
onset sepsis; R, Reserve; W, Watch.
Table 3 Antimicrobial resistance patterns in the NeoAMR network
Gram-negative cultures 









resistant to a 
glycopeptide
Bangladesh 49/58 (84) 47/58 (81) 0/1 (0)
Brazil 17/57 (30) 5/57 (9) 0/12 (0)
Cambodia 6/9 (67) 0/9 (0) 0/2 (0)
China 78/185 (42) 13/185 (7) 0/84 (0)
Colombia 25/42 (60) 1/42 (2) 0/50 (0)
Greece 8/13 (62) 0/13 (0) 0/1 (0)
India 286/562 (51) 154/562 (27) 35/265 (13)
Nigeria 26/36 (72) 7/36 (19) 5/11 (45)
South Africa 427/627 (68) 245/627 (39) 0/394 (0)
Thailand 12/46 (26) 10/46 (22) 0/11 (0)
NeoAMR, Neonatal AMR research network.
of ‘Reserve’ antibiotics. Of intended ‘Reserve’ antibiotic usage, 
4% was in EOS, 48% in LOS and 48% in meningitis. The use 
of Reserve antibiotics in the management of neonatal meningitis 
was particularly notable in India.
Although we do not have information about the blood 
culturing rate (ie, we do not know the positivity rate or the yield 
of pathogens), the ratio of positive blood cultures to admissions 
ranged from 0.2% (Bangladesh) to 40% (South Africa).
Of the 39 centres, 31 provided results of antimicrobial sensi-
tivity testing for their positive blood cultures. Cephalosporin 
resistance is found in the majority of Gram-negative isolates, 
with Bangladeshi and South African centres having the highest 
rates of carbapenem resistance (table 3). Glycopeptide resistance 
among Gram-positive isolates is a particular problem in Brazilian 
and Nigerian centres. Choice of ‘Reserve’ antibiotics for a local 
empirical antimicrobial guideline was associated with a higher 
total number of positive blood cultures per admission, suggesting 
that use of Reserve antibiotics may be guided by local microbi-
ology results rather than as broad-spectrum empirical therapy.
DIsCussIOn
To our knowledge, this is the first study to quantify differences in 
NNU resource allocation and choice of empirical antimicrobial 
therapy primarily in LMICs on a global scale, accompanied by 
AMR patterns of local isolates. There is significant variation in 
factors affecting neonatal care which will impact on the design 
of future neonatal sepsis trials, including the ratio of live births 
to the number of cots available locally, the level of staffing on 
site, the proportion of preterm admissions, access to a choice of 
empirical antimicrobial therapies, local blood culture rates and 
availability of antimicrobial susceptibility testing.
We divided these factors into three categories (figure 1). In 
the first category, accurate estimation of the admission rate rela-
tive to the local birth rate is needed to estimate the incidence 
of AMR sepsis and ease of access to intensive care support. 
Choice of empirical antimicrobial regimen may be a reflection 
of wider access to medicines at a country level. Gestational age 
is recognised as a particularly significant variable as preterm 
infants are more vulnerable to infection than term infants.9 Addi-
tionally, the unique pharmacokinetic profile of antimicrobials 
in this population10 may increase the risk of treatment failure. 
Colonisation by resistant bacteria and previous use of antibiotics 
are two factors which are used in clinical prediction scores, for 
example, for vancomycin-resistant enterococcus infection in an 
adult intensive care unit setting.11
Our data demonstrate the challenges faced when attempting 
global multicentre neonatal sepsis studies in settings with varied 
resource availability. Our study did not collect data on the acuity 
of bed usage, which is a key factor in the relationship between 
NNU staffing and mortality. There is currently no international 
standard for neonatal nursing training, although the Council 
of International Neonatal Nurses is increasingly playing a role 
in this area. There are also no published international data 
comparing neonatal nursing staffing ratios in different LMIC 
settings. The BAPM8 recommends staffing ratios of 1:1 for inten-
sive care beds, 1:2 for high dependency beds and 1:4 for special 
care baby unit admissions. While a recent systematic review12 
found that three of four studies reported correlation between 
lower neonatal staffing to patient ratios and higher mortality, 
and a reduction in staffing ratios for intensive care beds has been 
shown to correlate with increased mortality in a UK setting,13 
differences in the definition of staffing and a lack of evidence 
from an LMIC setting prevent the design of an optimal staffing 
approach.
When combined with results taken from the Global Antimi-
crobial Resistance, Prescribing, and Efficacy Among Neonates 
and Children (GARPEC) database,14 our data confirm that 
variation in choice of empirical antimicrobial regimens exists, 
despite the existence of global guidelines. One study of paedi-
atric Gram-negative blood stream infection (BSI) in the Pacific 
region found that for 309 episodes of BSI, 95 different empir-
ical regimens were prescribed (European Congress of Clinical 
Microbiology and Infectious Diseases 2018, abstract O0055). 
Future guidance emerging from a neonatal sepsis study to reduce 
global mortality from AMR-related sepsis is likely to be regional.
Our data show a worryingly high level of AMR, particularly 
in Gram-negative species. The findings suggest that particularly 
in Bangladesh and South Africa, choice of second-line antimi-
crobial therapy is increasingly limited. The WHO Access, Watch 
and Reserve (AWaRe) classification system of antimicrobials may 
be a useful guide to monitor usage of broad-spectrum antimicro-
bials; however, it is beyond the scope of our study to determine 
whether use of empirical antimicrobial regimens in particular 
categories is correlated with local AMR rates.
The total number of blood cultures taken at each site was not 
known, but the total number of positive cultures was assumed 
to be a proxy of blood culturing rates. Due to anonymisation of 





ber 6, 2019 at St G
eorge's University of London.
http://adc.bmj.com/
Arch D
is Child: first published as 10.1136/archdischild-2019-316816 on 24 August 2019. Downloaded from
 
5Li G, et al. Arch Dis Child 2019;0:1–6. doi:10.1136/archdischild-2019-316816
Original article
from the same patient or the same clinical episode. The rela-
tionship between blood culturing rates, contamination rate and 
BSI is unclear.15 Use of blood culture positivity with a resistant 
pathogen as a metric of exposure to AMR presents challenges, as 
blood culture positivity in neonates is low, even when a serious 
bacterial infection may be present.16 Underdetection of serious 
bacterial infection will result in novel interventions to reduce 
mortality being perceived as less effective in reducing neonatal 
mortality from AMR sepsis.
Neonatal colonisation status is affected by several factors, 
including maternal colonisation profile and immune function,17 
and is associated with invasive infection by colonising species.18 
Colonisation status may change during an inpatient stay on an 
NNU,19 and the precise relationship between colonisation and 
serious bacterial infection is not clearly understood, particularly 
in LMIC settings. The use of mortality as the endpoint in future 
trials of neonatal sepsis poses diagnostic challenges, as multiple 
pathologies are common in neonates and the differentiation of 
deaths with sepsis as opposed to attributable to sepsis will need 
to be considered. An emphasis on clinical presentations or physi-
ological observations which have a high positive predictive value 
for blood culture-positive sepsis4 is needed, as well as ensuring 
that the most common causes of death in the NNU population 
(eg, respiratory failure, intraventricular haemorrhage, massive 
pulmonary haemorrhage) are captured in future studies.20 
Mortality is also not the only outcome which should be consid-
ered. Neurodisability is a potentially preventable consequence 
of severe sepsis but much more difficult to assess because of the 
difficulties associated with long-term follow-up.21
COnClusIOn
Our data provide an important snapshot of how differences 
in NNU organisation and empirical antibiotic regimens may 
contribute to different clinical outcomes from AMR sepsis 
in different country settings. Further work is now required to 
understand how these differences can be captured in a future 
observational study designed to clarify how AMR influences 
neonatal mortality and, ultimately, how its impact can be reduced 
or prevented.
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